VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$28.75
Market Cap
$3.34B
52W High
$37.50
52W Low
$27.16
ADV30
2,021,233
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
| Sep 2025 | 0 | — | -98,561,000 | -90,787,000 | 739,415,000 | 100,376,000 | 26,385,000 |
| Jun 2025 | 0 | — | -74,574,000 | -65,561,000 | 827,851,000 | 33,880,000 | 32,390,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-340,330,000
Investing CF
$332,332,000
Financing CF
$88,167,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,005,871,000
Inventory
—
Receivables
—
ST Investments
$484,848,000
EBIT TTM
$-501,998,000
Pretax Income TTM
$-472,335,000
Interest Exp TTM
—
Analysts
18
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | — | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | — | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | — | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | — | -48,397,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.57
Max Pain — expiry 2026-06-18
max pain strike: $30.00 · spot: $29.63 · call oi: 12,713 · put oi: 4,692
Expected Move to 2026-06-18:
±$1.39
(4.67%) —
implied range
$28.24 –
$31.01
· ATM straddle on $29.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLX | Telix Pharmaceuticals Ltd | $3.24B | $9.56 | — |
| TLPPF | Telix Pharmaceuticals Ltd | $3.23B | $9.52 | — |
| OGN | Organon & Co. | $3.53B | $13.44 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $3.55B | $30.40 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.61B | $21.09 | — |
News headlines (Yahoo Finance, 1h cache)
Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation
2026-06-12 08:17 · Yahoo
Is Viking Therapeutics Stock Going to $100?
2026-06-12 05:35 · Yahoo
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
2026-06-11 11:05 · Yahoo
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
2026-06-10 21:50 · Yahoo
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
2026-06-10 17:47 · Yahoo
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
2026-06-04 21:45 · Yahoo
Should Viking’s VK2735 Obesity Program Advancements Require Action From Viking Therapeutics (VKTX) Investors?
2026-06-03 18:13 · Yahoo
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
2026-06-03 11:09 · Yahoo
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside
2026-06-02 23:43 · Yahoo
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
2026-06-02 15:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.